Chinese Hepatolgy ›› 2023, Vol. 28 ›› Issue (2): 135-145.
• Frontier, Exploration and Controversy • Next Articles
Received:2023-02-03
Online:2023-02-28
Published:2023-04-10
| [1] Sheena BS, Hiebert L, Han H, et al. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol,2022,7:796-829. [2] Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis,2016,16:1399-408. [3] Tu T, Zhang H. Viral integrations in chronic hepatitis B infection: purposeless passenger or problematic promoter of persistence? Hepatology,2022,76:15-17. [4] Tu T, Zhang H, Urban S. Hepatitis B virus DNA integration: in vitro models for investigating viral pathogenesis and persistence. Viruses,2021,13:180. [5] Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers, 2021,7:6. [6] Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol,2022,22:19-32. [7] Heim K, Neumann-Haefelin C, Thimme R, et al. Heterogeneity of HBV-specific CD8+ T-cell failure: implications for immunotherapy. Front Immunol,2019,10:2240. [8] Barili V, Vecchi A, Rossi M, et al. Unraveling the multifaceted nature of CD8 T cell exhaustion provides the molecular basis for therapeutic T cell reconstitution in chronic hepatitis B and C. Cells,2021,10:2563. [9] Burton AR, Pallett LJ, McCoy LE, et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest,2018,128:4588-603. [10] Salimzadeh L, Le Bert N, Dutertre CA, et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest,2018,128:4573-4587. [11] Neumann-Haefelin C, Thimme R. Entering the spotlight: hepatitis B surface antigen-specific B cells. J Clin Invest,2018,128:4257-4259. [12] Cornberg M, Lok AS, Terrault NA,et al; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B — report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. J Hepatol, 2020,72:539-557. [13] Milich DR. The concept of immune tolerance in chronic hepatitis B virus infection is alive and well. Gastroenterology,2016,151:801-804. [14] Kennedy PTF, Sandalova E, Jo J, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology,2012,143: 637-645. [15] Mason WS, Gill US, Litwin S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology, 2016,151(5):986-998.e4. [16] Suslov A, Meier MA, Ketterer S, et al. Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity. J Hepatol,2021,74:794-800. [17] Podlaha O, Gane E, Brunetto M, et al. Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. Sci Rep, 2019,9:10529. [18] Meier MA, Calabrese D, Suslov A, et al. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load. J Hepatol,2021,75:840-847. [19] Yeo YH, Ho HJ, Yang HI, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology, 2019,156(3):635-646.e9. [20] Papatheodoridis GV, Sypsa V, Dalekos GN, et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. J Hepatol, 2020,72: 1088-1096. [21] Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 2006,295:65-73. [22] Choi GH, Kim GA, Choi J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Aliment Pharmacol Ther, 2019,50:215-226. [23] Vaillant A. HBsAg, subviral particles, and their clearance in establishing a functional cure of chronic hepatitis B virus infection. ACS Infect Dis,2021,7:1351-68. [24] Lago BV, Mello FC, Kramvis A, et al. Hepatitis B virus subgenotype A1: evolutionary relationships between Brazilian, African and Asian isolates. PLoS One, 2014,9(8):e105317. [25] Kramvis A, Paraskevis D. Subgenotype A1 of HBV-tracing human migrations in and out of Africa. Antivir Ther,2013,18:513-5221. [26] Glebe D, Goldmann N, Lauber C, et al. HBV evolution and genetic variability: impact on prevention, treatment and development of antivirals. Antiviral Res,2021,186:104973. [27] Revill PA, Tu T, Netter HJ, et al. The evolution and clinical impact of hepatitis B virus genome diversity. Nat Rev Gastroenterol Hepatol, 2020,17:618-634. [28] Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology,2013,57:441-450. [29] Zhang H, Tu T. Approaches to quantifying hepatitis B virus covalently closed circular DNA. Clin Mol Hepatol,2022,28: 135-149. [30] Ghany MG, King WC, Lisker-Melman M, et al. Comparison of novel biomarkers with conventional HBV markers among untreated adults with chronic hepatitis B in North America. Hepatology,2021,74: 2395-2409. [31] Kramvis A, Chang KM, Dandri M, et al. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol,2022,19:727-745. [32] Butler EK, Gersch J, McNamara A, et al. Hepatitis B virus serum DNA and RNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection. Hepatology, 2018,68:2106- [33] Scholtès C, Hamilton AT, Plissonnier ML, et al. Performance of the cobas HBV RNA automated investigational assay for the detection and quantification of circulating HBV RNA in chronic HBV patients. J Clin Virol,2022,150-151:105150. [34] Giersch K, Allweiss L, Volz T, et al. Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol,2017,66:460-462. [35] Carey I, Gersch J, Wang B, et al. Pregenomic HBV RNA and hepatitis B corerelated antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy. Hepatology, 2020,72:42- [36] Mak LY, Wong DKH, Cheung KS, et al. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther, 2018,47:43-54. [37] Inoue T, Kusumoto S, Iio E, et al. Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepatol,2021,75:302-310. [38] Lok J, Dusheiko G, Carey I, et al. Review article: novel biomarkers in hepatitis B infection. Aliment Pharmacol Ther,2022,56:760-776. [39] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology,2018,67:1560-1599. [40] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int,2016,10:1-98. [41] European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67: 370-398. [42] Lee MH, Yang HI, Liu J, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology,2013,58:546-554. [43] Chow N, Wong D, Lai CL, et al. Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion. Clin Infect Dis,2023,76(3):e801-e809. [44] Hsu YC, Suri V, Nguyen MH, et al. Inhibition of viral replication reduces transcriptionally active distinct hepatitis B virus integrations with implications on host gene dysregulation. Gastroenterology,2022,162(4):1160-1170.e1. [45] Wong GLH, Tse YK, Wong VWS, et al. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: a cohort study of 53,500 subjects. Hepatology,2015,62:684-693. [46] Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol,2018,68:672-681. [47] Suzuki K, Suda G, Yamamoto Y, et al. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. PLoS One, 2022,17(1):e0261760. [48] Dandri M, Petersen J. cccDNA maintenance in chronic hepatitis B — targeting the matrix of viral replication. Infect Drug Resist,2020,13:3873-386. [49] Hsu YC, Yeh ML, Wong GLH, et al. Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B. J Infect Dis,2021,224:1890-1899. [50] Yip TC, Wong GL, Chan HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol, 2019,70:361-370. [51] Yuan BH, Li RH, Huo RR, et al. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis. J Gastroenterol Hepatol,2022,37:782-794. [52] Kim WR, Telep LE, Jump B, et al. Risk of hepatocellular carcinoma in treatmentna?ve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States. Aliment Pharmacol Ther,2022,55:828-835. [53] Choi WM, Yip TCF, Lim YS, et al. Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. J Hepatol, 2022,76:186-194. [54] Park ES, Lee AR, Kim DH, et al. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol,2019,70: 1093-1102. [55] Velkov S, Protzer U, Michler T. Global occurrence of clinically relevant hepatitis B virus variants as found by analysis of publicly available sequencing data. Viruses,2020,12:1344. [56] Sonneveld MJ, Chiu SM, Park JY, et al. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. J Hepatol, 2022,76:1042-1050. [57] Berg T, Simon KG, Mauss S, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients — FINITE study. J Hepatol,2017,67:918-924. [58] Papatheodoridis GV, Lekakis V, Voulgaris T, et al. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion. J Hepatol,2022,77:1670-1689. [59] Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science,2014,343:1221-1228. [60] Marcellin P, Ahn SH, Ma X, et al. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology,2016,150(1):134-144.e10. [61] Maini MK, Burton AR. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat Rev Gastroenterol Hepatol,2019,16:662-675. [62] Bazinet M, P?ntea V, Placinta G, et al. Safety ad efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection na?ve to nucleos(t)ide therapy. Gastroenterology,2020,158:2180-2194. [63] Taverniti V, Ligat G, Debing Y, et al. Capsid assembly modulators as antiviral agents against HBV: molecular mechanisms and clinical perspectives. J Clin Med,2022,11: 1349. [64] Hui RWH, Mak LY, Seto WK, et al. RNA interference as a novel treatment strategy for chronic hepatitis B infection. Clin Mol Hepatol,2022,28:408-424. [65] Yuen MF, Schiefke I, Yoon JH, et al. RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection. Hepatology,2020,72: 19-31. [66] Yuen MF, Asselah T, Jacobson IM, et al. Effects of the siRNA JNJ-3989 and/or the capsid assembly modulator JNJ-6379 on viral markers of chronic hepatitis B: results from the REEF-1 study. In: Proceedings and Abstracts of the 2022 International Liver Congress, June 22-26, 2022. London: European Association for the Study of the Liver, 2022. [67] Agarwal K, Buti M, Van Bommel F, et al. Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from the REEF-2 study. In: Proceedings and Abstracts of the 2022 AASLD Liver Meeting, November 4-6, 2022. Washington, DC: American Association for the Study of Liver Disease, 2022. [68] Agarwal K, Lok J, Carey I, et al. A case of HBV-induced liver failure in the REEF-2 phase II trial: implications for finite treatment strategies in HBV ‘cure.’ J Hepatol,2022,77:245-248. [69] Yuen MF, Heo J, Jang JW, et al. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nat Med,2021,27:1725-1734. [70] Yuen MF, Lim SG, Plesniak R, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl J Med,2022,387:1957-1968. [71] Gehring AJ, Protzer U. Targeting innate and adaptive immune responses to cure chronic HBV infection. Gastroenterology,2019,156:325-337. [72] Michler T, Kosinska AD, Festag J, et al. Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice. Gastroenterology, 2020,158(6):1762-1775.e9. [73] Aliabadi E, Urbanek-Quaing M, et al. Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. Gut, 2022,71:2300-2312. [74] Wong GL-H, Hui VW-K, Yip TC-F, et al. Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma. Aliment Pharmacol Ther,2022,56: 869-877. [75] Shimakawa Y, Veillon P, Birguel J, et al. Residual risk of mother-to-child transmission of hepatitis B virus infection despite timely birth-dose vaccination in Cameroon (ANRS 12303): a single-centre, longitudinal observational study. Lancet Glob Health,2022,10(4):e521-e529. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
